Introduction:
Age-related clonal haemopoiesis (ARCH) in healthy individuals was initially observed through an increased skewing in X chromosome inactivation 1 . More recently, several groups reported that ARCH is driven by somatic mutations 2, 3 . The most prevalent ARCH mutations are in the DNMT3A and TET2 genes, previously described as drivers of myeloid malignancies. ARCH is associated with an increased risk for haematological cancers 2, 3 . ARCH also confers an increased risk for non-haematological diseases such as cardiovascular disease, atherosclerosis, and chronic ischemic heart failure, for which age is a main risk factor 4, 5 .
Whether ARCH is linked to accelerated ageing has remained unexplored.
The most accurate and commonly-used tools to measure age acceleration are epigenetic clocks. They are based on age-related methylation differences at specific CpG sites 6, 7 , correlating chronological age accurately with epigenetic age. Deviations from chronological age towards an increased epigenetic age have been associated with increased risk of earlier mortality and age-related morbidities 8, 9 . Here we present evidence of accelerated epigenetic age in individuals with ARCH.
Methods:

Study Cohorts
The Lothian Birth Cohorts (LBCs) of 1921 and 1936 are two longitudinal studies of ageing 10 .
Participants have been followed up every ~3 years, each for five waves, from the age of 70 (LBC1936) and 79 (LBC1921). Participants were community-dwelling, relatively healthy, and mostly lived in the City of Edinburgh or its surrounding area when recruited.
Genome-wide methylation and sequencing
Whole blood DNA methylation levels were assessed using the Illumina HumanMethylation450
BeadChip. Quality control details have been reported previously 11 . Genomic variants were determined in 1,148 LBC participants (n=873 and n=5 from waves 1 and 2 at mean ages 70 and 73 years, respectively in LBC1936; n=104 and n=166 at mean ages 79 and 87, respectively in LBC1921) with whole-genome sequencing (WGS) and methylation data. WGS data were .
Epigenetic Age Acceleration
Epigenetic age acceleration was calculated online (https://dnamage.genetics.ucla.edu/home).
We considered "BioAge4HAAdjAge'" and "AAHOAdjCellCounts'", which are adaptations of the original Hannum and Horvath clocks that upweight for age-associated cell counts and control for white blood cell counts, respectively 7 . Both epigenetic age estimates were regressed on chronological age to yield age acceleration residuals.
Statistical Analysis
Linear regression adjusting for sex and methylation batch was used to determine the association between ARCH status (predictor) and Age Acceleration (response). All analyses were conducted in R v3.5.0.
Results:
Of the ten most prevalent ARCH mutations 2 , we had sufficient sample size and sequencing depth to annotate the top six in the LBC. We identified 71 participants (from 1,148) with ARCH (6.2%). The gene-specific prevalence ranged between 1-37 cases with ARCH-variant allele frequencies ranging from 0.034-0.677 (Fig.1A) . Mutations in TET2 were exclusively frameshift and mutations detected in JAK2 (all V617F), SF3B1 and TP53 were exclusively missense.
ARCH status was associated with a significant increase in Horvath's epigenetic age acceleration: the increase was 4.2 (SE 0.9) years in LBC1936, and 5.1 (SE 1.0) years in LBC1921 (p=1.5x10 -6 and 1.4x10 -6 , respectively) (Fig. 1C) ), respectively. (Fig.1D) . These effect sizes are much larger than the sex differences in Horvath age acceleration, which were 0.75 (SE 0.4) years for men in LBC1936 (p=0.055), and 0.51 (SE 0.67) in LBC1921 (P=0.45) (Fig.1D) ) increase in LBC1936 and LBC1921, respectively (data not shown).
Discussion:
These results in the Lothian Birth Cohorts show a link between ARCH and age acceleration.
This is an important conceptual advance leading to two, not necessarily mutually exclusive, testable scenarios: Firstly, ARCH could be an underlying cause for systemic ageing, explaining its link to various non-haematological, age-related diseases. Here, treating ARCH would have an effect on both, non-haematological and haematological disease. Secondly, an ageing microenvironment could enable clonal haemopoiesis, in which case non-haematological would be correlated, but not driven by ARCH. Here, treating ARCH would only affect haematological disease.
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